R Hussain, SE Coupland, H Kalirai, A Taktak, A Eleuteri, BE Damato, C Groenewald, H Heimann

Arwin Groenewoud, Jie Yin, B. Ewa Snaar-Jagalska

Nathalie Dhomen, Piyushkumar A. Mundra, Richard Marais

Olivier Lanz et. al

C Canbezdi, M Tarin, A Houy, D Bellanger, T Popova, MH Stern, S Roman-Roman, S Alsafadi

A Eleuteri, AC Rola, H Kalirai, R Hussain, J Sacco, BE Damato, H Heimann, SE Coupland, AFG Taktak

RJ Nell, NV Menger, GPM Luyten, RM Verdijk, MC Madigan, MJ Jager, PA van der Velden

MM Wang, C Chen, MN Lynn, CR Figueiredo, WJ Tan, TS Lim, SE Coupland, ASY Chan

MJ Rodrigues

The authors elucidate the importance of studying the tumour´s environment, namely the presence of macrophage originated T-cells in poor prognosis cases.

MJ de Lange, RJ Nell, RN Lalai, M Versluis, ES Jordanova, GPM Luyten, MJ Jager, SH Van der Burg, WH Zoutman, T Van Hall, PA Van der Velden

The authors discuss future perspectives regarding the treatment of uveal melanoma (UM) and why the therapeutic regimen must be tailored to the biological tumor background.

JJ Sacco, H Kalirai, J Kenyani, CR Figueiredo, JM Coulson, SE Coupland

In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.

RD Carvajal, S Piperno-Neumann, E Kapiteijn, PB Chapman, S Frank, AM Joshua, JM Piulats, P Wolter, V Cocquyt, B Chmielowski, TRJ Evans, L Gastaud, G Linette, C Berking, J Schachter, MJ Rodrigues, AN Shoushtari, D Clemett, D Ghiorghiu, G Mariani, S Spratt, S Lovick, P Barker, E Kilgour, Z Lai, GK Schwartz, P Nathan

This research article may explain the unexpected response to immune checkpoint inhibitors in a few UM patients, opening the door to further clinical research to treat patients with MBD4-deficient tumors. 

MJ Rodrigues, A Houy, S Gardrat, T Popova, A Rampano, L Mobuchon, A Fiévet, RL Barnhill, V Servois, A Mouton, S Dayot, V Raynal, M Galut, M Putterman, S Tick, N Cassoux, S Roman-Roman, FC Bidard, O Lantz, P Mariani, S Piperno-Neumann, MH Stern

In this article, we review genetic prognostic indicators in UM, also comparing available genetic tests, addressing the clinical application of genetic prognostication and discussing future perspectives for improving genetic prognostication in UM.

MJ Jager, M Dogrusöz

We report on recent advances in using zebrafish as a model in cancer studies—with specific focus on four cancer types—where zebrafish has contributed to novel discoveries or approaches to novel therapies.

AI Idilli, F Precazzini, MC Mione, V Anelli

Early changes resulting in gain of chromosome 8q may activate macrophage infiltration, while sequential loss of BAP1 expression seems to drive T cell infiltration in UM.

G Gezgin, TH Van Essen, WGM Kroes, GPM Luyten, PA Van der Velden, V Walter, RM Verdijk, T Van Hall, SH Van der Burg, MJ Jager, M Dogrusöz

 The CLPTM1L region contains risk alleles for uveal melanoma susceptibility, suggesting that CLPTM1L could play a role in uveal melanoma oncogenesis.

L Mobuchon, A Battistella, C Bardel, G Scelo, A Renoud, A Houy, N Cassoux, M Milder, G Cancel-Tassin, O Delattre, C Besse, A Boland, JF Deleuze, DG Cox, MH Stern

Combining information on AJCC staging and chromosome 3 and 8q status allows a more accurate prognostication in UM. The prognostic value of the AJCC staging system can be improved by adding information regarding chromosome 3 and 8q status.

M Dogrusöz, M Bagger, SG Van Duinen, WGM Kroes, CA Ruivenkamp, S Bohringer, KK Andersen, GPM Luyten, JF Kiilgaard, MJ Jager

The authors provide an overview of uveal melanoma keypoints and a list of the main unmet clinical needs.

S Piperno-Neumann, JM Piulats, M Goebeler, I Galloway, I Lugowska, JC Becker, P Vihinen, J Van Calster, T Hadjistilianou, R Proença, JM Caminal, M Rogasik, JY Blay, E Kapiteijn

In this paper, the authors discuss the various treatments evaluated in the setting of metastatic uveal melanoma. Trough the understanding of uveal melanoma’s biology, immunotherapy efficacy may be improved after priming the tumour from immunologically “cold” to “hot” with a new molecule.

J Yang, DK Manson, BP Marr, RD Carvajal

This study implies that the metastatic proclivity of UM is "set in stone" early in tumor evolution and may explain why advances in primary treatment have not improved survival.

MG Field, MA Durante, H Anbunathan, LZ Cai, CL Decatur, AM Bowcock, S Kurtenbach, JW Harbour

Analysis of kinome-wide signalling network dynamics has the potential to reveal actionable drug targets and inhibitors of potential therapeutic benefit for UM patients.

FP Bailey, K Clarke, H Kalirai, H Kenyani, H Shahidipour, F Falciani, JM Coulson, JJ Sacco, SE Coupland, PA Eyers

Study resulting from a Rare Tumour Project of The Cancer Genome Atlas (TCGA) Project where a molecular taxonomy of four clinical subsets of uveal melanoma (UM) subtypes is identified.

AG Robertson, J Shih, C Yau, EA Gibb, J Oba, KL Mungall, JM Hess, V Uzunangelov, V Walter, L Danilova, TM Lichtenberg, M Kucherlapati, PK Kimes, M Tang, A Penson, R Akbani, CA Bristow, KA Hoadley, L Iype, MT Chang, TCGA Research Network, AD Cherniack, C Benz, GB Mills, RGW Verhaak, KG Griewank, I Felau, JC Zenklusen, JE Gershenwald, L Schoenfield, AJ Lazar, MH Abdel-Rahman, S Roman-Roman, MH Stern, CM Cebulla, MD Williams, MJ Jager, SE Coupland, B Esmaeli, C Kandoth, SE Woodman, O Babur

Improved surgical techniques and laboratory methods yielded successful cytology and genetic information in 99% and 89% of cases, respectively.

M Angi, H Kalirai, A Taktak, R Hussain, C Groenewald, BE Damato, H Heimann, SE Coupland

G Gezgin, SJ Luk, J Cao, DM Van der Steen, RS Hagedoorn, D Krijgsman, PA Van der Velden, MG Field, GPM Luyten, K Szuhai, JW Harbour, ES Jordanova, MHM Heemskerk, MJ Jager, M Dogrusöz

The findings nominate RasGRP3 as a therapeutic target for cancers driven by oncogenic GNAQ/11.

X Cheng, Q Wu, P Depeille, P Cheng, S Thornton, H Kalirai, SE Coupland, JP Roose, BC Bastian

This paper validates the Liverpool Uveal Melanoma Prognosticator Online (LUMPO) in a cohort of patients treated at the University of California-San Francisco (UCSF).

SW DeParis, A Taktak, A Eleuteri, W Enanoria, H Heimann, SE Coupland, BE Damato

Weak correlation between oncogenic GNAQQ209P mutation and sustained ERK1/2-MAPK activation.

MA Mouti, C Dee, SE Coupland, AF Hurlstone

This paper examines the presence and distribution of umor-associated macrophages (TAMs) and infiltrating T lymphocytes (TILs) in mUM within the liver.

Y Krishna, C McCarthy, H Kalirai, SE Coupland

These results strongly argue against generalizing the observations made in mesothelioma to all cancer syndromes with BAP1 deficiencies.

M Schoumacher, S Le Corre, A Houy, E Mulugeta, MH Stern, S Roman-Roman, R Margueron

These findings suggest that PTP4A3-related subcellular localization of MMP14 is an important event in metastasis induction.

S Maacha, O Anezo, M Foy, G Liot, L Mery, C Laurent, X Sastre-Garau, S Piperno-Neumann, N Cassoux, N Planque, S Saule

RFA can be used to treat liver metastases to spare the hepatic parenchyma. RFA ± liver surgery and liver surgery alone demonstrate similar survival times.

P Mariani, MM Almubarak, M Kollen, M Wagner, C Plancher, R Audollent, S Piperno-Neumann, N Cassoux, V Servois

This study provides a better understanding of the mechanisms underlying splicing alterations induced by mutant SF3B1 in cancer, and reveals a role for alternative branchpoints in disease.

S Alsafadi, A Houy, A Battistella, T Popova, M Wassef, E Henry, F Tirode, A Constantinou, S Piperno-Neumann, S Roman-Roman, M Dutertre, MH Stern

Molecular and chromosomal classification strongly predicting metastatic death has to be used to identify genetic profiles and pathways involved in the pathogenesis of uveal melanoma leading to new targeted therapeutic strategies.

P Mariani, V Servois, S Piperno-Neumann

This paper's findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target.

JW Harbour, MD Onken, ED Roberson, S Duan, L Cao, LA Worley, ML Council, KA Matatall, C Helms, AM Bowcock

Constitutive activation of the pathway involving the GNAQ or GNA11 genes appears to be a major contributor to the development of uveal melanoma.

CD Van Raamsdonk, KG Griewank, MB Crosby, MC Garrido, S Vemula, T Wiesner, AC Obenauf, W Wackernagel, G Green, N Bouvier, MM Sozen, G Baimukanova, R Roy, A Heguy, I Dolgalev, R Khanin, K Busam, MR Speicher, J O'Brien, BC Bastian

This panel of 16 uveal melanoma xenografts represents a useful preclinical tool for both pharmacologic and biological assessments.

F Nemati, X Sastre-Garau, C Laurent, J Couturier, P Mariani, L Desjardins, S Piperno-Neumann, O Lantz, B Asselain, C Plancher, D Robert, I Peguillet, MH Donnadieu, A Dahmani, MA Bessard, D Gentien, C Reyes, S Saule, E Barillot, S Roman-Roman, D Decaudin

Epigenetic regulation of tumour suppressor genes provides an attractive mechanism for tumours in which mutations and structural changes are rare.

PA Van der Velden, W Maat